Sign in
Enrolling by invitationNo phase

Long Term Follow-Up for RGX-111

Key facts

Who runs it
REGENXBIO Inc.
Where
Orange, United StatesSee the siteAlso in 1 other country, 1 site
Trial code
Status
Enrolling by invitation
People taking part
21 people, planned
Started
24 Jul 2023
Expected to end
Sept 2027
Type of study
Observational
Record updated
29 April 2026

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • To be eligible, a participant must have previously received RGX-111 in a separate parent trial
  • Participant or participant's legal guardian(s) is/(are) willing and able to provide written, signed informed consent

Who cannot take part

  • None

Where in United States

Also in 1 other country, 1 site

  • Children's Hospital of Orange CountyOrange, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

RGX-111-5101 is a long-term follow up study that evaluates the long-term safety and efficacy of RGX-111 in participants who have received RGX-111 (a gene therapy intended to deliver a functional copy of the alpha-L-iduronidase gene (IDUA) to the central nervous system) in a separate parent study.

The group in the trial

  • RGX-111 Recipients

    Subjects who have received RGX-111 in a separate parent study.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Long-term Follow-up Study to Evaluate the Safety of RGX-111
Record updated
29 April 2026